Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin

Abstract

The need for the delivery of insulin by injection can be reduced or eliminated by delivering an aerosolized monomeric insulin formulation. Repeatability of dosing and more particularly the repeatability of the blood concentration versus time profile is improved relative to regular insulin. The blood concentration versus time profile is substantially unaffected by specific aspects of the patient's breathing maneuver at delivery. Further, the rate at which blood glucose is lowered is increased by the use of monomeric insulin. Particles of insulin and in particular monomeric insulin delivered to the surface of lung tissue will be absorbed into the circulatory system. The monomeric insulin may be a dry powder but is preferably in a liquid formulation delivered to the patient from a hand-held, self-contained device which automatically releases an aerosolized burst of formulation. The device includes a sensor which is preferably electronic which measures inspiratory flow and volume which measurement can be used to control the point of drug release.

1 .- 20 . (canceled)  
   
   
       21 . A method of improving reproducibility of insulin delivered via lungs by inhalation, comprising: 
 (a) aerosolizing a formulation comprising insulin lispro;    (b) inhaling the aerosolized formulation into the lungs of a patient, the formulation being inhaled with a first total inhaled volume;    (c) allowing particles of formulation to settle in the lungs, migrate into the patient's circulatory system and thereby increase the concentration to a first maximum level in the patient's blood in a first period of time;    (d) repeating the aerosolizing of a formulation comprised of insulin lispro;    (e) inhaling the aerosolized formulation of (d) into the lungs of a patient, the formulation being inhaled with a second total inhaled volume different from the first total inhaled volume;    (f) allowing particles of formulation to settle in the lungs, migrate into the patient's circulatory system and thereby increase the concentration of formulation to a second maximum level in the patient's blood in a second period of time;    whereby the difference between the first total inhaled volume and the second total inhaled volume effects the difference between the first maximum level of formulation and the second maximum level of formulation less than if the formulation were comprised of regular recombinant insulin.    
   
   
       22 . The method of  claim 21 , further comprising: 
 measuring the patient's glucose level.    
   
   
       23 . The method of  claim 22 , further comprising: 
 repeating the (a) aerosolizing, (b) inhaling and (c) allowing steps in a manner so as to maintain the patients glucose level in a desired range.    
   
   
       24 . The method of  claim 23 , wherein each aerosolizing (a) step is carried out to create an aerosolized dose containing substantially the same amount of insulin.  
   
   
       25 . The method of  claim 24 , further comprising: 
 orally administering a sulfonylurea drug to the patient.    
   
   
       26 . The method of  claim 25 , wherein the sulfonylurea drug is selected from the group consisting of acetohexamide, chlorpropamide, tolazamide, tolbutamide, glipzide and glyburide.  
   
   
       27 . The method of  claim 21 , further comprising: 
 heating air surrounding the aerosolized formulation.    
   
   
       28 . The method of  claim 27 , wherein the aerosol comprises particles having a diameter in the range of about 1.0 to about 4.0 microns.  
   
   
       29 . The method of  claim 21 , further comprising: 
 repeating the (a) aerosolizing; (b) inhaling and (c) allowing steps a plurality of times wherein the total inhaled volume is different in each of any different inhaling steps.    
   
   
       30 . The method of  claim 29 , wherein the formulation is aerosolized by being forced through a porous membrane from a disposable container.  
   
   
       31 . The method of  claim 21 , wherein the formulation is a liquid formulation comprised of a pharmaceutically acceptable carrier and insulin lispro and is present in a container comprising an opening covered by a porous membrane; and 
 wherein the aerosolizing (a) is carried out by moving the formulation through the pores of the membrane, the pores having a cross-sectional configuration with a small end opening of 0.25 to 6.0 microns in diameter and a large end opening of 2 to 20 times the diameter of the small end.    
   
   
       32 . The method of  claim 21 , wherein the first total inhaled volume is about half the second total inhaled volume.  
   
   
       33 . The method of  claim 21 , wherein the first total inhaled volume is in a range of about 2 to 2.5 liters and the second total inhaled volume is in a range of from about 4 to 5 liters.